Risk-adapted treatment of acute promyelocytic leukemia: Results from the international consortium for childhood APL
- Testi, Anna Maria
- Pession, Andrea
- Diverio, Daniela
- Grimwade, David
- Gibson, Brenda
- Cardoso de Azevedo, Amilcar
- Moran, Lorena
- Leverger, Guy
- Elitzur, Sarah
- Hasle, Henrik
- van der Werff ten Bosch, Jutte
- Smith, Owen
- de Rosa, Marisa
- Piciocchi, Alfonso
- Lo Coco, Francesco
- Foà, Robin
- Locatelli, Franco
- Kaspers, Gertjan J. L.
DOIAbstract
Pediatric acute promyelocytic leukemia (APL) can be cured with all-trans retinoic acid (ATRA) and anthracycline. However, most published trials have employed high cumulative doses of anthracyclines. Here, we report the outcome of newly diagnosed APL patients enrolled in the International Consortium for Childhood APL (ICC-APL-01) trial, which reduced anthracycline exposure but extended that of ATRA. The study recruited 258 children/adolescents with molecularly/cytogenetically proven APL. Patients were stratified into standard-risk (SR) and high-risk (HR) groups according to baseline white blood cell counts (<10 3 109/L or ‡10 3 109/L); both groups received identical induction treatment with ATRA and 3 doses of idarubicin. Two or 3 blocks of ...
Add to ORKG